welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
study id #: NCT03532542
condition: Duchenne Muscular Dystrophy
status: enrolling by invitationpurpose:
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
intervention: Casimersen, Golodirsen
mechanism of action: Exon-skipping to promote dystrophin production
last updated: July 06, 2020
start date: August 2, 2018
estimated completion: August 10, 2026
phase of development: Phase 3
size / enrollment: 260
- Number of patients with serious adverse events (SAEs) [Time Frame: Up to 30 days after the last infusion of study drug (assessed up to 148 weeks)]]
• Eligible Sexes: male
• Is between 7 and 23 years of age, inclusive, at enrollment.
Study of SRP-4045 and SRP-4053 in DMD PatientsThe main objective of this study is to e...
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation DystrophinopathyThe primary objective of this study is t...
A Study of Tadalafil for Duchenne Muscular DystrophyThe main purpose of this study is to det...
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsHappy New Year! As 2019 kicks off, our P...
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug ApplicationOn February 14, 2019, Sarepta Therapeuti...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...